EJNMMI Radiopharmacy and Chemistry, 2020 Purpose The chimeric monoclonal antibody (mAb) chDAB4 (APOMAB®) targets the Lupus associated (La)/Sjögren Syndrome-B (SSB) antigen, which is over-expressed in tumors but only becomes available for antibody binding in dead tumor cells.
Vasilios Liapis +6 more
doaj +1 more source
Evaluation of macrocyclic hydroxyisophthalamide ligands as chelators for zirconium-89. [PDF]
PLoS ONE, 2017 The development of bifunctional chelators (BFCs) for zirconium-89 immuno-PET applications is an area of active research. Herein we report the synthesis and evaluation of octadentate hydroxyisophthalamide ligands (1 and 2) as zirconium-89 chelators. While
Nikunj B Bhatt +5 more
doaj +1 more source
Tracking of [14C]Polystyrene Nanoplastics in Pregnant Mice
Advanced Science, EarlyView.This study investigates [14C]polystyrene nanoplastic ([14C]PS) translocation in late‐stage pregnant mice after intranasal (0.5 mg of [14C]PS on GD12, GD14, and GD16, n = 6) and intravenous administration (1.5 mg of [14C]PS on GD16, n = 6). 14C‐radiolabel allows quantitative tracking of unmodified polystyrene nanoplastics.
Olga Khaybullina +2 more
wiley +1 more source
Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology
Frontiers in Pharmacology, 2016 Selection of the right drug for the right patient is a promising approach to increase clinical benefit of targeted therapy with monoclonal antibodies (mAbs).
Yvonne W.S. Jauw +7 more
doaj +1 more source
Analyzing of Production Conditions of 89Zr in the Particle Accelerator
Cumhuriyet Science Journal, 2019 Nowadays 89Zr is outstanding PET radionuclidewith its physical half-life (t1/2 ~ 78 hours), useful decay specifications andso that it is suitable for antibody-based immuno-PET.
Özge Kozguş Güldü +4 more
doaj +1 more source
Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example
EJNMMI Research, 2021 Background 89Zirconium-immuno-positron emission tomography (89Zr-immuno-PET) is used for assessment of target status to guide antibody-based therapy.
Marc C. Huisman +7 more
doaj +1 more source
High-energy threshold reaction rates on 0.8 GeV proton-irradiated thick Pb-target
, 2007 This works presents results of activation-aided determination of threshold reaction rates in 92 209Bi, natPb, 197Au, 181Ta, 169Tm, natIn, 93Nb, 64Zn, 65Cu, 63Cu, 59Co, 19F, and 12C samples and in 121 27Al samples.
Batyaev, V. F. +8 more
core +1 more source
Smart Nanotechnologies for Multimodal Neuromodulation and Brain Interfacing
Advanced Science, EarlyView.Recent advances in smart nanotechnologies are expanding the toolbox for brain interfacing, from wireless neuromodulation and high‐resolution sensing to targeted delivery within the central nervous system. By combining responsive nanomaterials with bioinspired design, these platforms enable multimodal interactions with neurons and glia, while also ...
Tommaso Curiale +6 more
wiley +1 more source
Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics
British Journal of Clinical Pharmacology, EarlyView.Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay +5 more
wiley +1 more source
Cyclotron production of high–specific activity 55Co and in vivo evaluation of the stability of 55Co metal-chelate-peptide complexes [PDF]
, 2015 This work describes the production of high–specific activity 55 Co and the evaluation of the stability of 55 Co-metal-chelate-peptide complexes in vivo. 55 Co was produced via the 58 Ni(p,α) 55 Co reaction and purified using anion exchange chromatography
Bollinger, Elizabeth +6 more
core +9 more sources